ClinicalTrials.gg
Active, not recruitingNCT03600441FORERUNNERUpdated Apr 10, 2025

Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma

A Phase 2 interventional study of Abexinostat in Follicular Lymphoma, sponsored by Xynomic Pharmaceuticals, Inc.. Active, not recruiting at 15 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-10.

Sponsored by Xynomic Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
139
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,187 studies in Lymphoma, Follicular with a site in United States — 128 open to participants now, 217 under way, 20 of them phase 3. Lymphoma, Follicular · United States.

Planned enrollment
181st of 1,017
139 · median 38
Started
2018
with 32 others
Phase 2
379 of 1,187
34 open now
Primary completion
2027-12
later than 127 of 216 live
Registered
888th of 1,187
by date

Among the 1,187 studies in Lymphoma, Follicular with a site in United States, this one is the 181st largest by planned enrollment of the 1,017 interventional ones that give a count, is one of 33 that started in 2018, is one of 379 in phase 2, reaches primary completion later than 127 of the 216 other live ones, and was the 888th registered.

Lymphoma, Follicular

1,893 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

128 of the 1,187 studies in Lymphoma, Follicular with a site in United States are open now. Recruiting first, the newest first:

123 more — sign in →

All 128 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 226 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,187 studies in Lymphoma, Follicular with a site in United States, or all of them as a file.
02

Study summary

This study in patients with relapsed/refractory follicular lymphoma who have undergone at least 3 lines of therapy. Patients will receive abexinostat 80 mg (4 × 20 mg tablets) twice a day (BID) in a "one week on, one week off" schedule.

Read the detailed description

Patients will be evaluated for objective response, Duration of Response (DOR), Progression Free Survival (PFS), Clinical Benefit Rate (CBR), Overall survival (OS), safety and tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and changes in health related quality of life. Patients may receive treatment until disease progression, death, unacceptable toxicity, or withdrawal of consent. An independent data safety monitoring committee (iDMC) will evaluate the data pertaining to the futility and decide whether the study should stop or continue to the second stage. If the study continues to the second stage, a total of 139 patients will be studied.

03

Conditions studied

  • Follicular Lymphoma

Keywords

  • cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is able to understand and voluntarily sign an document before any study related assessments/procedures are conducted.
  • Has confirmed Grade 1, 2, or 3a follicular lymphoma.
  • Has follicular lymphoma that has after (progressed after 6 months from the start of therapy) or is refractory to the last (no response or progression within 6 months from the start of therapy) and needs treatment (must have at least 1 lymph node or extranodal lymphoid radiologically measuring ≥ 3 cm in its longest diameter).
  • Female patients must fulfil the following criteria:

    a. Be of non-, defined as follows: i. (ie, ≥ 1 year without any menses) prior to Screening, or ii. Documented surgically sterile (≥ 1 month prior to Screening)

  • Male patients must agree not to donate sperm starting from the time of Screening, throughout the study, and until after 90 days following the last dose.
  • Use highly effective forms of (women of childbearing potential only), which include the following:

    i. Consistent and correct use of established oral contraception ii. Established intrauterine device or intrauterine system iii. Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository.

  • Female patients must agree not to breastfeed starting from the time of Screening, throughout the study, and until after 90 days following the last dose.
  • Male patients and their female spouse/partners who are of childbearing potential must use highly effective contraception methods consisting of 2 forms of birth control (at least 1 of which must be a barrier method) from the time of Screening, throughout the study, and until after 90 days following the last dose.
  • Male patients must agree not to donate sperm starting from the time of Screening, throughout the study, and until after 90 days following the last dose.

Exclusion criteria

Exclusion Criteria:

  • Has diagnosis of Grade 3b follicular lymphoma, or transformation to diffuse large B-cell lymphoma
  • Has a history of central nervous system lymphoma (either primary or secondary).
  • Has had prior treatment with abexinostat.
  • Has had stem cell transplant within the last 6 months, or autologous stem cell transplant within the last 3 months before enrollment
  • Has any types of cardiac impairment at the time of enrollment
  • Has received any medication within 30 days or 5 half-lives prior to Day 1, whichever is longer
  • Has prior history of , other than follicular lymphoma, unless the patient has been free of the disease for ≥ 3 years
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
139 participants (estimated)

Study arms

  • Experimental
    Abexinostat

    Abexinostat tablets will be administered orally at 80 mg (4 × 20 mg tablets) BID (twice a day) 4 hours apart for 7 days in a "one week on, one week off" schedule (on Days 1 to 7 and Days 15 to 21 of each 28-day cycle).

    Drug: Abexinostat

Interventions

  • Abexinostat tosylate salt is formulated into an oral tablet formulation and is available in 20 mg strength.

06

What researchers measure

Primary outcomes

  1. Clinical effect of abexinostat

    Complete response (CR) or partial response (PR) according to the Lugano 2014 criteria as determined by an Independent Review Committee (IRC).

    Time frame: Time frame up to 100 months

Secondary outcomes

  1. Duration of response

    Duration of response defined as the time from first documented evidence of CR or PR until disease progression or death from any cause among patients who achieve an objective response, according to the Lugano 2014 criteria as determined by an IRC.

    Time frame: At the end of cycle 2 (each cycle is 28 days) and through study completion, assessed up to 100 months.

  2. Progression free survival

    Defined as the time from the start of treatment until disease progression or death assessed using the Lugano 2014 criteria as determined by an IRC.

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months

  3. Clinical Benefit

    Defined as the best from CR, PR, or stable disease (SD) according to the Lugano 2014 criteria as determined by an IRC.

    Time frame: At the end of cycle 2 (each cycle is 28 days) and through study completion, assessed up to 100 months.

  4. Overall survival

    Defined as the time from the start of treatment until death from any cause or last contact.

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months

  5. Duration of response

    Defined as the time from first documented evidence of CR or PR from any cause among patients who achieve an objective response, according to the RECIL 2017 as determined by an IRC. Duration of response will be evaluated once more using the RECIL 2017 with the inclusion of Minor Response (MR) lasting ≥ 6 months.

    Time frame: At the end of cycle 2 (each cycle is 28 days) or from date of randomization until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months

  6. Incidence of adverse events

    Safety as measured by the incidence of adverse events

    Time frame: At the end of cycle 2 (each cycle is 28 days) or from date of randomization until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months

  7. Incidence of serious adverse events

    Safety as measured by the serious of adverse events (SAE)

    Time frame: At the end of cycle 2 (each cycle is 28 days) or from date of randomization until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months

  8. Incidence of non-serious adverse events

    Safety as measured by the non-serious of adverse events

    Time frame: At the end of cycle 2 (each cycle is 28 days) or from date of randomization until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months

  9. Change in the interval corrected for heart rate (QTc) interval

    Change from baseline in the QTc interval.

    Time frame: At the end of cycle 2 (each cycle is 28 days) or from date of randomization until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months

07

Study locations

15 sites
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2018 (actual). Primary completion is estimated for Dec 2027, 112 months after the start.

Of 48 industry-sponsored phase 2 interventional studies under Lymphoma, Follicular, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 52. This study's planned 112 months is above that.

Counting every sponsor, half of 199 studies reached it within 57 months; a quarter within 31 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2018
First posted
Jul 26, 2018
StartActual
Aug 27, 2018
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2029
Last update
Apr 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03600441
Lead sponsor
Xynomic Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Jul 26, 2018
Start date
Aug 27, 2018
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Apr 10, 2025

Study contacts

Connie W Batlevi, MD,PhD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abexinostat

Start the discussion